Lanso 30 Capsule
by Square Pharmaceuticals Limited
৳6.04
Lantid 30
Opsonin Pharma Limited
1 Pc
৳5.00
1 Strip = 6 Pcs
৳30.00
1 Box = 3 Strips
৳90.00
Dosage: Lansoprazole 30mg
Form: Capsule
Generic name(s): Lansoprazole 30mg
Available (pcs): 0
Prescription required: No
LANTID 30MG | Opsonin Pharma Ltd | Order Online - OsudPotro
Generic
Lansoprazole
Indications
Lansoprazole is prescribed for the following conditions:
- Treatment of an active duodenal ulcer in the short term
- Maintenance of duodenal ulcers that have healed
- Treatment of active benign gastric ulcers in the short term
- Treatment of active erosive esophagitis in the short term
- Maintenance of erosive esophagitis healing
- Pathological hypersecretory disorders such as Zollinger-Ellison Syndrome are examples of pathological hypersecretory conditions.
- Eradication of H. pylori to minimize the incidence of recurrence of duodenal ulcers
Pharmacology
Lansoprazole is a substituted benzimidazole that is also known as a PPI owing to its ability to inhibit the H+/K+ ATPase enzyme system in the gastric parietal cell and hence impede the final phase of acid production. Basal and stimulated acid are both inhibited.
Dosage & Administration
Benign gastric ulcer: 30 mg daily in the morning for 8 weeks.
Duodenal ulcer: 30 mg daily in the morning for 4 weeks; maintenance 15 mg.
NSAID-associated duodenal or gastric ulcer: 15-30 mg daily for 4 weeks, followed by a further 4 weeks if not fully healed.
Zollinger-Ellison syndrome (and other hypersecretory conditions): Initially 60 mg once daily adjusted according to response; daily doses of 120 mg or more is given in two divided doses.
Gastroesophageal reflux disease: 30 mg daily in the morning for 4 weeks, followed by a further 4 weeks if not fully healed; maintenance 15-30 mg daily.
Acid-related dyspepsia: 15-30 mg daily in the morning for 2-4 weeks.
Duodenal ulcer: 30 mg daily in the morning for 4 weeks; maintenance 15 mg.
NSAID-associated duodenal or gastric ulcer: 15-30 mg daily for 4 weeks, followed by a further 4 weeks if not fully healed.
Zollinger-Ellison syndrome (and other hypersecretory conditions): Initially 60 mg once daily adjusted according to response; daily doses of 120 mg or more is given in two divided doses.
Gastroesophageal reflux disease: 30 mg daily in the morning for 4 weeks, followed by a further 4 weeks if not fully healed; maintenance 15-30 mg daily.
Acid-related dyspepsia: 15-30 mg daily in the morning for 2-4 weeks.
Interaction
Lansoprazole appears to be a selective inhibitor of the cytochrome P-450 monooxygenase system; there may be an influence on hepatic clearance, but no clinically significant interactions have been reported to far. There is significant ambiguity about Lansoprazole's impact on the oral combination contraceptive pill. A second round of evaluation is under underway. Physiological effects similar to those seen with Omeprazole are expected to occur because to the decrease in gastric acid, which is likely to impact bacterial colonization of the stomach and duodenum as well as vitamin B12 absorption.
Contraindications
Lansoprazole is not recommended for people who have a history of hypersensitivity to any component of the formulation.
Side Effects
Severe or permanent side effects: Carcinoid tumors may be induced by severe acid suppression, and serum gastrin levels may increase. Serum gastrin levels rise over the first three months of therapy and thereafter stabilize, but at a lower level than in pernicious anaemia. In individuals with Helicobacter pylori infection, long-term therapy with a proton pump inhibitor may hasten the development of atrophic gastritis.
Symptomatic side effect: Dose-dependent diarrhoea occurs at a rate of around 4% at 30 mg per day, increasing to 8% at 60 mg per day. Headache affects 2-3% of all treated people.
Pregnancy & Lactation
Unless there are strong reasons, lansoprazole should be avoided during pregnancy.
Precautions & Warnings
Gastric cancer should be checked out. Impairment of the liver. Lactation and pregnancy
Therapeutic Class
Proton Pump Inhibitor
Storage Conditions
Keep at 25° C.
Pharmaceutical Name
Opsonin Pharma Ltd.
